Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Radiation Injuries 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 158Paclitaxel 152Bevacizumab 85Gemcitabine 48liposomal doxorubicin 47Taxes 47Topotecan 41Cisplatin 34pembrolizumab 33Cyclophosphamide 28olaparib 25Immunoglobulin G 24Disulfides 24Specimen Handling 20Docetaxel 20Drug Therapy 19Magnetic Resonance Spectroscopy 17niraparib 16Doxorubicin 16Biopsy 15mirvetuximab soravtansine 14Hyperthermic Intraperitoneal Chemotherapy 13rucaparib 12Nivolumab 12Cytoreduction Surgical Procedures 10Albumin-Bound Paclitaxel 10veliparib 9Platinum 9Chemotherapy, Adjuvant 9130-nm albumin-bound paclitaxel 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fallopian Tube Neoplasms × Poly A × Clear all
NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

Sun Yat-sen University

Phase 2 Not yet recruiting
44 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡